PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Diabetes & Metabolism Journal10.4093/dmj.2020.00012020442213Fibrates Revisited: Potential Role in Cardiovascular Risk ReductionNam Hoon Kim, Sin Gon Kimhttps://e-dmj.org/pdf/10.4093/dmj.2020.0001, https://e-dmj.org/DOIx.php?id=10.4093/dmj.2020.0001, http://e-dmj.org/upload/pdf/dmj-44-213.pdf
Atherosclerosis10.1016/j.atherosclerosis.2005.04.00220051822199-207Fibrates and coronary risk reductionGeorge Steinerhttps://api.elsevier.com/content/article/PII:S0021915005002558?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915005002558?httpAccept=text/plain
Atherosclerosis10.1016/j.atherosclerosis.2011.04.02020112172492-498Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysisMeng Lee, Jeffrey L. Saver, Amytis Towfighi, Jessica Chow, Bruce Ovbiagelehttps://api.elsevier.com/content/article/PII:S0021915011003662?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915011003662?httpAccept=text/plain
Canadian Journal of Cardiology10.1016/j.cjca.2014.07.70920143010S371-S372EXERCISE REVISITED: A CARDIOVASCULAR RISK REDUCTION STRATEGYK. Hildebrand, H. Conradsonhttps://api.elsevier.com/content/article/PII:S0828282X14011878?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0828282X14011878?httpAccept=text/plain
Nutrition, Metabolism and Cardiovascular Diseases10.1016/s0939-4753(03)80118-72003135329Treatment of massive hypertriglyceridemias resistant to pufa and fibrates: A possible role for the coenzyma Q10?https://api.elsevier.com/content/article/PII:S0939475303801187?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0939475303801187?httpAccept=text/plain
Progress in Cardiovascular Nursing10.1111/j.0889-7204.2001.0990801.x200716130-32Oxidative Stress and the Role of Antioxidants in Cardiovascular Risk ReductionLori L. Schoonoverhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.0889-7204.2001.0990801.x
Therapeutics and Clinical Risk Management10.2147/tcrm.s5546920151133Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosisDaniel Duerschmied, Christoph Bode, Philipp Diehlhttps://www.dovepress.com/getfile.php?fileID=26284
Multiple Risk Factors in Cardiovascular Disease10.1007/978-94-011-0039-7_361995295-306Fibrates: Modes of ActionAlberico L. Catapanohttp://link.springer.com/content/pdf/10.1007/978-94-011-0039-7_36
Nutrition and Dietary Supplements10.2147/nds.s6025201085Role of green tea in reduction of cardiovascular risk factorsCharalambos Vlachopoulos, Alexopoulos, Stefanadishttps://www.dovepress.com/getfile.php?fileID=7209
Contemporary Endocrinology10.1007/978-1-60761-424-1_252015423-438Fibrates: Risk Benefits and Role in Treating DyslipidemiasMin Jun, Vlado Perkovichttp://link.springer.com/content/pdf/10.1007/978-1-60761-424-1_25